Search PubMed⌕ Search

Biomedical subjects

F Bauters

Publications and source records attributed to F Bauters.

At least 199 records · Page 11Linked to original sources

[Primary neuromeningeal manifestation, isolated for a long period, of acute lymphoblastic leukemia].

The course of acute leukaemias, particularly of the lymphoblastic type, is very frequently complicated by the development of neuromeningeal localisations of the disease. They may, more rarely, be presenting initial lesions, their origin being confirmed clinically and/or biologically, but it is exceptional that they remain a strictly isolated expression of the affection. A case is reported of a 16-year-old adolescent with leukaemic meningitis, in whom haematological tests (blood counts, bone marrow smear, iliac medullary biopsy, lymph node biopsy) gave negative results over a period of at least two months. Based on the findings in this case, the significance of early neuromeningeal localisations of acute leukaemias is discussed.

Adolescent↗

[Hematological toxicity of ticlopidine? (author's transl)].

Four cases of bone marrow aplasia, with temporary agranulocytosis (one of them fatal) are described in patients treated with Ticlopidine, an anti-aggregating drug prescribed for prevention of thromboembolic disease. These data suggest that a systematic hematological assessment would be required in the first three months after initiation of Ticlopidine therapy.

Aged↗

[Treatment of idiopathic thrombopenic purpura. Results obtained in a series of 219 cases].

From 1971 to 1979, 219 patients with idiopathic thrombocytopenic purpura (ITP) were seen and all subjected to the same scheme of treatment. there were 150 adults and 69 children ( less than 15 years old), 140 were females and 79 males. At presentation, 152 had had symptoms for less than 3 months ("recent" ITP) and 67 could be immediately considered as chronic ITP (since they had had symptoms for more than 3 months). Whatever the duration of symptoms, corticosteroid therapy (1.5 to 2 mg/kg/day during 3 weeks) was first administered. At the end of the treatment, normal platelet count was achieved in 92.5% (136/147) of the "recent" ITP and 77% (51/66) of the chronic ITP. One year later, a complete remission was still evident in 65% (96/147) of the "recent" ITP but in only 14% (9/66) of the chronic ITP 3 of whom had died of hemorrhage. So the total number of patients with chronic ITP, non responders to prednisone therapy was 110. In 19 cases, the further progression was unknown and 16 patients were in partial remission. Splenectomy, indicated in 75 patients, was performed in only 64. After 2 weeks the platelet count was normal in 94% (60/64) of the patients. The success (platelets greater than 100 000/microliter) was pronounced, one year after splenectomy, in 86% (55/64) of them. A splenic sequestration of the radiolabelled platelets appeared to be the only positive prognostic factor. Of 15 patients treated with azathioprine (2.5 mg/kg/day) over a 1 to 5 year period, 8 have gone into remission and 7 failed to respond (2 died from hemorrhage). Excluding the 19 patients with an unknown progression, the results are finally as follows: remissions (or success): 84.5% (169/200), partial remission: 8% (16/200), complete failure: 7.5% (15/200) with 2.5% (5/200) of deaths directly related to the disease. A total of 75 patients have been followed for more than 5 years and 8 of them (11%) relapsed following 4 to 6 years of remission.

Adolescent↗

Acquired von Willebrand's syndrome in the course of Waldenström's disease.

Acquired von Willebrand's syndrome with a regressive evolution is described in a 66 year old man with Waldenström's disease. An inhibitor electively directed against Ristocetin cofactor activity has been demonstrated, active in vitro after incubation at 37 degrees C. Serum fractionation showed that the inhibitor was independent of the monoclonal IgM and subsequent purification that it was IgG in nature. The results permit its classification as an auto-antibody.

Aged↗

Application of the study of prognostic factors to the treatment of childhood (less than 20 years old) acute lymphoblastic leukemia.

405 children with acute lymphoblastic leukemia were stratified according to age, initial leucocytes count, lymph nodes, liver and spleen size, into three prognostic classes I, II, III. Protocol 08 LA 74 which they were applied included: 1)initial randomization between Prednisone, Vincristine, Daunorubicin or the same plus Cyclophosphamide for induction and reinductions; 2)doses adjustments to prognostic factors, increased doses being given to increased risk patients; 3)comparison between intrathecal Methotrexate and intrathecal Methotrexate plus Ara-C in addition to skull irradiation for CNS prophylaxis; 4)L-Asparaginase consolidation for all patients; 5)maintenance by 6-Mercaptopurine and Methotrexate in all patients and reinductions. The most striking conclusions to date are the improvement for increased risk patients, the frequency of primary testicular relapses contrasting with the low rate of meningitis, the prognostic implication of sex, the influence on remission duration of the number of courses necessary to achieve complete remission, the importance of using Cox Method to improve the identification of prognostic groups.

Adolescent↗

[Detection of platelet antibodies in idiopathic thrombocytopenic purpura (author's transl)].

The amount of IgG present on the surface of platelets (platelet-bound IgG, or PBIgG) was measured using a quantitative antiglobulin consumption assay developed by Dixon et al. (1975). Normal platelets or platelets from patients with thrombocytopenia due to a decreased production had less than 10 X 10(-15) g of IgG/platelet. Studied were 364 blood samples drawn from 196 patients; 173 patients had idiopathic thrombocytopenic purpura; 65 (93 %) of 70 in the acute phase of their disease had elevated PBIgG (values up to 100 times greater than the normal); 98 (76.5 %) of 128 blood samples from patients during a chronic phase had abnormally high PBIgG but the levels of IgG were generally lower than those observed in the acute phase; 75 (75 %) of 100 samples from patients in remission did not have pathologically increased PBIgG. Usually when the platelet count improved (after prednisone therapy or after splenectomy), PBIgG decreased. The PBIgG determination was not useful for predicting the response to prednisone therapy or the further evolution of the disease, except when PGIgG remained elevated after high-dose prednisone therapy; this generally implied a poor prognosis. PBIgG have also been found elevated in other diseases such as lupus erythematosus and in one case of chronic lymphocytic leukemia. This assay may be of a great clinical interest, especially for the diagnosis of ITP.

Antibodies↗